• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

PCV13: Effective Against First-Episode CAP in Older Adults

Slideshow

The 13-valent pneumococcal conjugate vaccine reduced nearly by half vaccine-type community acquired pneumonia in adults aged 65 years and older.

Related Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Interview with Kelly Moore, MD, MPH, president, chief executive officer, Immunization Action Coalition
Related Content
Breathlessness in Middle-Aged Adults Linked to Overweight/Obesity, Stress, and Respiratory Disease / Image credit: ©tassel78/AdobeStock

Breathlessness in Middle-Aged Adults Linked to Overweight/Obesity, Stress, and Respiratory Disease

April 15th 2024
Article

Results of a recent study support the importance of lifestyle interventions to reduce the burden of breathlessness in middle-aged adults.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Older, Mentally Altered Adults at Greatest Risk for Inappropriate Diagnosis of CAP

Older, Mentally Altered Adults at Greatest Risk for Inappropriate Diagnosis of CAP

April 5th 2024
Article

More than 1 in 10 older adults were misdiagnosed with community-acquired pneumonia and nearly all were treated with a full course of antibiotics, a new study found.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

May 20th 2022
Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

©Kateryna_Kon/stock.adobe.com

Merck's 21-Valent Adult-Specific Pneumococcal Vaccine Accrues New Phase 3 and Real World Data

March 19th 2024
Article

The novel 21-valent pneumococcal vaccine remains on track for the FDA PDUFA date of June 17, 2024; Merck adds this new data to the body of positive evidence.

Boehringer Ingelheim Will Cap Out of Pocket Costs for Inhalers at $35 per Month / image credit inhalers ©beltado/stock.adobe.com

Boehringer Ingelheim Will Cap Out of Pocket Costs for Inhalers at $35 per Month

March 7th 2024
Article

The monthly out of pocket cap applies to all BI inhalers and goes into effect on June 1, 2024.

© 2024 MJH Life Sciences

All rights reserved.